Greenland Mines Ltd (GRML)

$0.41 -0.06 (-12.37%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 2,885,800
Avg Vol 3,719,506
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 11%
Beta N/A
Analysts Strong Buy
Price Target N/A
Latest News on GRML
Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML

Mar 12, 2026, 10:27 AM EDT - 4 days ago

Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML

KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

Mar 4, 2026, 8:00 AM EST - 12 days ago

KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)

Feb 24, 2026, 8:00 AM EST - 20 days ago

Klotho Neurosciences (NASDAQ:KLTO) Initiates Development of the "Klotho Clock," a Diagnostic Biological Aging and Longevity Clock that Unlocks Health Testing Through Epigenetics and Artificial Intelligence (AI)

Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence

Feb 18, 2026, 8:00 AM EST - 26 days ago

Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence

Klotho Neurosciences to Present at the Biotech Showcase 2026

Jan 8, 2026, 8:00 AM EST - 2 months ago

Klotho Neurosciences to Present at the Biotech Showcase 2026

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Nov 7, 2025, 10:03 AM EST - 4 months ago

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Oct 16, 2025, 8:00 AM EDT - 5 months ago

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences Announces Expiration of Letter of Intent

Oct 7, 2025, 6:20 PM EDT - 5 months ago

Klotho Neurosciences Announces Expiration of Letter of Intent

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Sep 30, 2025, 8:30 AM EDT - 5 months ago

Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Aug 18, 2025, 8:30 AM EDT - 7 months ago

Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

Aug 12, 2025, 6:00 AM EDT - 7 months ago

Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Jul 25, 2025, 9:05 PM EDT - 8 months ago

UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Jul 24, 2025, 1:30 PM EDT - 8 months ago

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Jul 22, 2025, 10:21 AM EDT - 8 months ago

Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Jul 16, 2025, 6:00 AM EDT - 8 months ago

Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

Jul 10, 2025, 5:00 AM EDT - 8 months ago

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

This Penny Stock Exploded 500% In June: What You Need To Know

Jun 30, 2025, 11:07 AM EDT - 9 months ago

This Penny Stock Exploded 500% In June: What You Need To Know

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Jun 30, 2025, 2:00 AM EDT - 9 months ago

Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

Jun 24, 2025, 5:00 AM EDT - 9 months ago

Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived Population

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

Jun 18, 2025, 7:00 AM EDT - 9 months ago

KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

Jun 16, 2025, 7:00 AM EDT - 9 months ago

KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

Jun 10, 2025, 11:00 AM EDT - 9 months ago

Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

Jun 9, 2025, 7:00 AM EDT - 10 months ago

KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco

Jan 8, 2025, 11:00 AM EST - 1 year ago

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco